Alloy Therapeutics and Biogen Announce Multi-Target Collaboration

The partnership will leverage Alloy's AntiClastic™ ASO platform to accelerate oligonucleotide drug development.

Apr. 7, 2026 at 2:28pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a collection of polished, geometric glass and metal laboratory equipment arranged elegantly on a clean, white background, conveying a sense of precision and innovation in the biotechnology industry.A conceptual still life captures the precision and innovation behind Alloy Therapeutics' collaboration with Biogen to advance oligonucleotide drug development.Boston Today

Alloy Therapeutics, a biotechnology company focused on accelerating drug discovery, has entered into a multi-target collaboration and license agreement with Biogen, a leading pharmaceutical company. The collaboration will leverage Alloy's proprietary AntiClastic™ antisense oligonucleotide (ASO) platform to advance the development of innovative oligonucleotide therapeutics.

Why it matters

This partnership builds on the companies' past work together, including Biogen's use of Alloy's AI-enabled transgenic mouse platform. The collaboration aims to combine Alloy's expertise in oligonucleotide drug discovery with Biogen's strengths in translating breakthrough research into impactful therapies.

The details

Under the terms of the agreement, Alloy Therapeutics will grant Biogen the rights to utilize its AntiClastic™ ASO platform to develop oligonucleotide therapeutics targeting multiple undisclosed targets. Alloy will receive an upfront payment, as well as potential milestone payments and royalties on any products that are successfully developed and commercialized through the collaboration.

  • The collaboration was announced on April 7, 2026.

The players

Alloy Therapeutics

A biotechnology company focused on accelerating drug discovery through its proprietary platforms, including the AntiClastic™ ASO platform.

Biogen

A leading pharmaceutical company known for its scientific leadership and ability to translate breakthrough research into impactful therapies.

Got photos? Submit your photos here. ›

The takeaway

This collaboration between Alloy Therapeutics and Biogen represents a strategic partnership that leverages the strengths of both companies to accelerate the development of innovative oligonucleotide therapeutics, potentially leading to new treatment options for patients.